Crossref
Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias
Clinical Leukemia · 2006
DOI: 10.3816/clk.2006.n.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Leukemia, 2006. Verfasst von Tariq I. Mughal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mughal, T. I. (2006). Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias. Clinical Leukemia. https://doi.org/10.3816/clk.2006.n.003
Vancouver
Mughal TI. Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias. Clinical Leukemia. 2006. doi:10.3816/clk.2006.n.003
BibTeX
@article{Mughal2006,
author = {Mughal, Tariq I.},
title = {Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias},
journal = {Clinical Leukemia},
year = {2006},
doi = {10.3816/clk.2006.n.003}
}
EUVIMED